Massachusetts Financial Services Co. MA Sells 42,171 Shares of Prestige Consumer Healthcare Inc. $PBH

Massachusetts Financial Services Co. MA trimmed its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 6.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 590,297 shares of the company’s stock after selling 42,171 shares during the quarter. Massachusetts Financial Services Co. MA owned 1.20% of Prestige Consumer Healthcare worth $36,835,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. UMB Bank n.a. increased its stake in Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after purchasing an additional 144 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Prestige Consumer Healthcare by 2.0% during the second quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock valued at $747,000 after buying an additional 182 shares during the last quarter. Cerity Partners LLC increased its position in shares of Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after acquiring an additional 218 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares in the last quarter. Finally, F m Investments LLC raised its holdings in shares of Prestige Consumer Healthcare by 0.5% in the 2nd quarter. F m Investments LLC now owns 53,369 shares of the company’s stock worth $4,262,000 after acquiring an additional 259 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president directly owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $67.07 on Thursday. The business’s fifty day simple moving average is $61.72 and its 200 day simple moving average is $64.93. The company has a current ratio of 3.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a 12 month low of $57.25 and a 12 month high of $90.04. The firm has a market capitalization of $3.22 billion, a P/E ratio of 16.64, a price-to-earnings-growth ratio of 2.03 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The business’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PBH. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Jefferies Financial Group lowered their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target for the company in a report on Wednesday, September 24th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $85.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).